Chengyuan Gu

机构：Shanghai Medical College of Fudan University, Soochow University, Fudan University Shanghai Cancer Center, Shanghai Cancer Institute, First Affiliated Hospital of Soochow University, First Hospital of Qinhuangdao

发表论文 85 篇 · 总被引 773 次 · h-index 16

代表论文

• Longitudinal MRI‐Driven Multi‐Modality Approach for Predicting Pathological Complete Response and B Cell Infiltration in Breast Cancer (2025 · Advanced Science · 被引 40)
• Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study (2023 · Journal of Immunotherapy · 被引 25)
• Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study (2023 · The Lancet Haematology · 被引 23)
• Impaired megakaryopoiesis due to aberrant macrophage polarization via BTK/Rap1/NF-κB pathway in sepsis-induced thrombocytopenia (2024 · Molecular Therapy · 被引 10)
• Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial (2023 · Chinese Medical Journal · 被引 9)
• Inherited mutations in Chinese patients with upper tract urothelial carcinoma (2023 · Cell Reports Medicine · 被引 8)